Related Experiment Video
Updated: Jun 16, 2025
09:21
Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
Published on: January 29, 2019
36.1K
High-purity AAV vector production utilizing recombination-dependent minicircle formation and genetic coupling.
Hao Liu1, Nan Liu1, Chen Zhou1
1Department of Genetic and Cellular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.
EMBO Molecular Medicine
|May 16, 2025
Summary
A new AAVPureMfg method significantly enhances recombinant adeno-associated virus (rAAV) purity by reducing bacterial DNA and increasing full capsids. This innovation offers a safer, more potent gene therapy vector production alternative.
Area of Science:
- Molecular Biology
- Gene Therapy Vector Production
Background:
- Recombinant adeno-associated virus (rAAV) is a key gene therapy vector.
- Traditional triple transfection methods yield impurities, impacting rAAV safety and potency.
Purpose of the Study:
- Introduce AAVPureMfg for high-purity rAAV production.
- Address limitations of current rAAV manufacturing processes.
Main Methods:
- Utilized recombination-dependent minicircle formation and genetic coupling.
- Employed Bxb1-mediated excision for transgene cassette removal.
- Developed iterations for enhanced vector genome homogeneity.
Main Results:
- Reduced prokaryotic DNA contaminants 10- to 50-fold compared to triple transfection.
- Increased the full capsid ratio up to threefold.
- Demonstrated streamlined production for various rAAV constructs.
Conclusions:
- AAVPureMfg offers a broadly applicable method for high-purity rAAV.
- This approach overcomes inherent limitations of triple transfection.
- Provides a cost-effective and easy-to-implement solution for rAAV manufacturing.
